Long-term Outcomes for Prostate Cancer Patients Under Active Surveillance

Strategic Insights -

Research conducted at the University of California San Francisco (UCSF) has provided new insights into the long-term outcomes for prostate cancer patients under active surveillance. A study published in European Urology Oncology investigated the outcomes for 774 men who were stable patients on active surveillance for 10 to 15 years. The study found that the majority of patients remained upgrade-free, with 56% remaining upgrade-free at 10 years, 45% at 12 years, and 21% at 15 years. The study also found that patients with higher body mass index (BMI) and biopsy core positivity were at a higher risk of upgrade.

Key Takeaways:

  • The study investigated the long-term outcomes for 774 stable prostate cancer patients under active surveillance for 10 to 15 years.
  • The majority of patients remained upgrade-free, with 56% remaining upgrade-free at 10 years and 21% at 15 years.
  • Patients with higher body mass index (BMI) and biopsy core positivity were at a higher risk of upgrade.
  • The study found that prostate cancer-specific survival was 100% at 15 years, with overall survival rates ranging from 95% to 98% at various time points.
  • The study concluded that active surveillance can be continued in this patient population, and that deintensification may be considered in select patients.

Statistics:

  • 774 patients met the inclusion criteria for the study.
  • 56% of patients remained upgrade-free at 10 years, 45% at 12 years, and 21% at 15 years.
  • Major upgrade-free survival rates were 88%, 83%, and 61% at 10, 12, and 15 years, respectively.
  • Treatment-free survival rates were 86%, 83%, and 73% at 10, 12, and 15 years, respectively.
  • Metastasis-free survival rates were 99%, 99%, and 98% at 10, 12, and 15 years, respectively.
  • Overall survival rates ranged from 95% to 98% at various time points.

Sources:

  • European Urology Oncology, 2025;8(2):380-386.
  • NewsRx. Studies Conducted at University of California San Francisco (UCSF) on Disease Progression Recently Reported (Determining Long-term Prostate Cancer Outcomes for Active Surveillance Patients Without Early Disease Progression: Implications for ...). Health & Medicine Week. May 16, 2025; p 6743.